Literature DB >> 19244104

Control of HIF-1alpha expression by eIF2 alpha phosphorylation-mediated translational repression.

Keyi Zhu1, Waikin Chan, John Heymach, Miles Wilkinson, David J McConkey.   

Abstract

Hypoxia inducible factor 1alpha (HIF-1alpha) plays a central role in regulating tumor angiogenesis via its effects on vascular endothelial growth factor (VEGF) transcription, and its expression is regulated through proteasome-mediated degradation. Paradoxically, previous studies have shown that proteasome inhibitors (PI) block tumor angiogensis by reducing VEGF expression, but the mechanisms have not been identified. Here, we report that PIs down-regulated HIF-1alpha protein levels and blocked HIF-1alpha transcriptional activity in human prostate cancer cells. PIs induced phosphorylation of the translation initiation factor 2alpha (eIF2alpha), which caused general translational repression to inhibit HIF-1alpha expression. Furthermore, PIs induced HIF-1alpha accumulation in LNCaP-Pro5 cells depleted of eIF2alpha via siRNA transfection and in MEFs expressing a phosphorylation-deficient mutant form of eIF2alpha. Finally, PIs failed to induce eIF2alpha phosphorylation or translational attenuation in DU145 or 253JB-V cells, and, in these cells, PIs promoted HIF-1alpha accumulation. Our data established that PIs down-regulated HIF-1alpha expression in cells that display activation of the unfolded protein response by stimulating phosphorylation of eIF2alpha and inhibiting HIF-1alpha translation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19244104      PMCID: PMC4188393          DOI: 10.1158/0008-5472.CAN-08-4103

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  38 in total

Review 1.  The development of proteasome inhibitors as anticancer drugs.

Authors:  Julian Adams
Journal:  Cancer Cell       Date:  2004-05       Impact factor: 31.743

2.  Regulation of protein synthesis by hypoxia via activation of the endoplasmic reticulum kinase PERK and phosphorylation of the translation initiation factor eIF2alpha.

Authors:  Constantinos Koumenis; Christine Naczki; Marianne Koritzinsky; Sally Rastani; Alan Diehl; Nahum Sonenberg; Antonis Koromilas; Bradly G Wouters
Journal:  Mol Cell Biol       Date:  2002-11       Impact factor: 4.272

3.  NF-kappa B as a therapeutic target in multiple myeloma.

Authors:  Teru Hideshima; Dharminder Chauhan; Paul Richardson; Constantine Mitsiades; Nicholas Mitsiades; Toshiaki Hayashi; Nikhil Munshi; Lenny Dang; Alfredo Castro; Vito Palombella; Julian Adams; Kenneth C Anderson
Journal:  J Biol Chem       Date:  2002-02-28       Impact factor: 5.157

4.  Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts.

Authors:  Simon Williams; Curtis Pettaway; Rendu Song; Christos Papandreou; Christopher Logothetis; David J McConkey
Journal:  Mol Cancer Ther       Date:  2003-09       Impact factor: 6.261

Review 5.  The endoplasmic reticulum stress response in immunity and autoimmunity.

Authors:  Derrich J Todd; Ann-Hwee Lee; Laurie H Glimcher
Journal:  Nat Rev Immunol       Date:  2008-09       Impact factor: 53.106

Review 6.  Development of the proteasome inhibitor Velcade (Bortezomib).

Authors:  Julian Adams; Michael Kauffman
Journal:  Cancer Invest       Date:  2004       Impact factor: 2.176

Review 7.  Hypoxia inducible factor-1alpha as a cancer drug target.

Authors:  Garth Powis; Lynn Kirkpatrick
Journal:  Mol Cancer Ther       Date:  2004-05       Impact factor: 6.261

8.  The proteasome inhibitor bortezomib stabilizes a novel active form of p53 in human LNCaP-Pro5 prostate cancer cells.

Authors:  Simon A Williams; David J McConkey
Journal:  Cancer Res       Date:  2003-11-01       Impact factor: 12.701

Review 9.  The proteasome as a target for cancer therapy.

Authors:  Peter M Voorhees; E Claire Dees; Bert O'Neil; Robert Z Orlowski
Journal:  Clin Cancer Res       Date:  2003-12-15       Impact factor: 12.531

Review 10.  Targeting HIF-1 for cancer therapy.

Authors:  Gregg L Semenza
Journal:  Nat Rev Cancer       Date:  2003-10       Impact factor: 60.716

View more
  26 in total

1.  HSP90 inhibitors in the context of heat shock and the unfolded protein response: effects on a primary canine pulmonary adenocarcinoma cell line.

Authors:  Arin N Graner; Justin E Hellwinkel; Alex M Lencioni; Helen J Madsen; Tessa A Harland; Paul Marchando; Ger J Nguyen; Mary Wang; Laura M Russell; Lynne T Bemis; Thomas J Anchordoquy; Michael W Graner
Journal:  Int J Hyperthermia       Date:  2016-12-20       Impact factor: 3.914

2.  Fresh Garlic Extract Induces Growth Arrest and Morphological Differentiation of MCF7 Breast Cancer Cells.

Authors:  Suhasini Modem; Stephen E Dicarlo; Thipparthi R Reddy
Journal:  Genes Cancer       Date:  2012-02

3.  Activation of EGFR by proteasome inhibition requires HB-EGF in pancreatic cancer cells.

Authors:  C M Sloss; F Wang; M A Palladino; J C Cusack
Journal:  Oncogene       Date:  2010-03-08       Impact factor: 9.867

4.  Ornithine Decarboxylase Is Sufficient for Prostate Tumorigenesis via Androgen Receptor Signaling.

Authors:  Amita Shukla-Dave; Mireia Castillo-Martin; Ming Chen; Jose Lobo; Nataliya Gladoun; Ana Collazo-Lorduy; Faisal M Khan; Vladimir Ponomarev; Zhengzi Yi; Weijia Zhang; Pier P Pandolfi; Hedvig Hricak; Carlos Cordon-Cardo
Journal:  Am J Pathol       Date:  2016-10-19       Impact factor: 4.307

5.  Bortezomib represses HIF-1α protein expression and nuclear accumulation by inhibiting both PI3K/Akt/TOR and MAPK pathways in prostate cancer cells.

Authors:  Christina D Befani; Panagiotis J Vlachostergios; Eleana Hatzidaki; Anna Patrikidou; Sophia Bonanou; George Simos; Christos N Papandreou; Panagiotis Liakos
Journal:  J Mol Med (Berl)       Date:  2011-09-10       Impact factor: 4.599

6.  Inhibition of hypoxia-inducible factor-1alpha (HIF-1alpha) protein synthesis by DNA damage inducing agents.

Authors:  Jessica Jie Wei Lou; Yee Liu Chua; Eng Hui Chew; Jie Gao; Martin Bushell; Thilo Hagen
Journal:  PLoS One       Date:  2010-05-07       Impact factor: 3.240

7.  Bortezomib downregulates MGMT expression in T98G glioblastoma cells.

Authors:  Panagiotis J Vlachostergios; Eleana Hatzidaki; Nikolaos E Stathakis; George K Koukoulis; Christos N Papandreou
Journal:  Cell Mol Neurobiol       Date:  2013-01-20       Impact factor: 5.046

8.  Hypoxia-inducible factor-1α (HIF-1α) promotes cap-dependent translation of selective mRNAs through up-regulating initiation factor eIF4E1 in breast cancer cells under hypoxia conditions.

Authors:  Tingfang Yi; Evangelos Papadopoulos; Patrick R Hagner; Gerhard Wagner
Journal:  J Biol Chem       Date:  2013-05-10       Impact factor: 5.157

9.  ATF4 promotes bone angiogenesis by increasing VEGF expression and release in the bone environment.

Authors:  Hongli Jiao; Shuai Li; Ke Zhu; Huiling Cao; Deborah L Galson; Zhongfang Zhao; Xi Zhao; Yumei Lai; Jie Fan; Hee-Jeong Im; Di Chen; Guozhi Xiao
Journal:  J Bone Miner Res       Date:  2013-09       Impact factor: 6.741

10.  Proteasome inhibitors activate autophagy as a cytoprotective response in human prostate cancer cells.

Authors:  K Zhu; K Dunner; D J McConkey
Journal:  Oncogene       Date:  2009-11-02       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.